Eltrombopag Improved Platelet Counts in Thrombocytopenic MDS Patients
The use of the thrombopoietin receptor agonist eltrombopag was clinically effective at raising platelet counts in patients with lower-risk myelodysplastic syndromes with severe thrombocytopenia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news
More News: Cancer & Oncology | Hematology | Legislation | Myelodysplastic Syndrome | Thrombocytopenia